Psychiatric changes in patients treated with levodopa. I. The clinical experiment.
作者信息
Knopp W
出版信息
Neurology. 1970 Dec;20(12):23-30.
PMID:4924341
Abstract
摘要
相似文献
1
Psychiatric changes in patients treated with levodopa. I. The clinical experiment.
Neurology. 1970 Dec;20(12):23-30.
2
Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
Neurology. 1970 Dec;20(12):6-13.
3
[Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
Shinkei Kenkyu No Shimpo. 1971;15(1):267-85.
4
Psychiatric changes in patients treated with levodopa. I. The clinical experiment.
Neurology. 1970 Dec;20(12):Suppl:23-30.
5
[Clinical study of L-dopa in Parkinson's disease].
Brux Med. 1972 Dec;52(12):851-60.
6
Permanent dementia in idiopathic Parkinsonism treated with levodopa.
Arch Neurol. 1973 Oct;29(4):276-8. doi: 10.1001/archneur.1973.00490280088014.
7
Levodopa and amantadine in the treatment of Parkinsonism.
Practitioner. 1972 Apr;208(246):499-504.
8
The Eaton Collaborative Study of levodopa therapy in parkinsonism: a summary.
Neurology. 1970 Dec;20(12):46-59.
9
[Psychiatric complications of L-Dopa treatment of parkinsonism].
Tidsskr Nor Laegeforen. 1973 Apr 10;93(10):680-5.
10
Start hesitation--a side effect of long-term levodopa therapy.
N Engl J Med. 1973 May 24;288(21):1113-5. doi: 10.1056/NEJM197305242882108.
引用本文的文献
1
Monoamine reuptake inhibitors in Parkinson's disease.
Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25.
2
Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.
Rev Neurosci. 2013;24(3):267-78. doi: 10.1515/revneuro-2013-0004.
3
Psychiatric side effects of medications prescribed in internal medicine.
Dialogues Clin Neurosci. 2003 Jun;5(2):155-65. doi: 10.31887/DCNS.2003.5.2/rcasagrandetango.
4
The effects of levodopa therapy in patients with Parkinson's disease. I. Clinical response.
Can Med Assoc J. 1972 Nov 18;107(10):973-6.
5
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.
Drugs. 1971;2(4):262-400. doi: 10.2165/00003495-197102040-00002.
Zotero 插件